Insulin detemir

Insulin detemir

Clinical data
ATC code	A10AE05 (WHO)
Pharmacokinetic data
Bioavailability	60% (when administered s.c.)
Elimination half-life	5-7 hours
Identifiers
CAS Number	169148-63-4
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C267H402N64O76S6
Molar mass	5913

WikiDoc Resources for Insulin detemir
Articles
Most recent articles on Insulin detemir Most cited articles on Insulin detemir Review articles on Insulin detemir Articles on Insulin detemir in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Insulin detemir Images of Insulin detemir Photos of Insulin detemir Podcasts & MP3s on Insulin detemir Videos on Insulin detemir
Evidence Based Medicine
Cochrane Collaboration on Insulin detemir Bandolier on Insulin detemir TRIP on Insulin detemir
Clinical Trials
Ongoing Trials on Insulin detemir at Clinical Trials.gov Trial results on Insulin detemir Clinical Trials on Insulin detemir at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Insulin detemir NICE Guidance on Insulin detemir NHS PRODIGY Guidance FDA on Insulin detemir CDC on Insulin detemir
Books
Books on Insulin detemir
News
Insulin detemir in the news Be alerted to news on Insulin detemir News trends on Insulin detemir
Commentary
Blogs on Insulin detemir
Definitions
Definitions of Insulin detemir
Patient Resources / Community
Patient resources on Insulin detemir Discussion groups on Insulin detemir Patient Handouts on Insulin detemir Directions to Hospitals Treating Insulin detemir Risk calculators and risk factors for Insulin detemir
Healthcare Provider Resources
Symptoms of Insulin detemir Causes & Risk Factors for Insulin detemir Diagnostic studies for Insulin detemir Treatment of Insulin detemir
Continuing Medical Education (CME)
CME Programs on Insulin detemir
International
Insulin detemir en Espanol Insulin detemir en Francais
Business
Insulin detemir in the Marketplace Patents on Insulin detemir
Experimental / Informatics
List of terms related to Insulin detemir

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Insulin detemir is a long-lasting human insulin analogue for maintaining the basal level of insulin. Novo Nordisk markets it under the trade name Levemir. It is an insulin analogue in which to the lysine amino acid at position B29 a fatty acid (myristic acid) is bound. It is quickly resorbed after which in the blood it binds to albumin through the fat acid at position B29. It then slowly dissociates from this complex.

In a clinical study (see ref 2) which compared the efficacy and safety of using Levemir for the treatment of patients with type 2 diabetes who had suboptimal glycemic control while receiving maximally tolerated doses of metformin and sulfonylurea (common tablet therapies for type 2 diabetes), it was found that, "At 24 weeks, A1C (glycosylated hemoglobin) had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and from 8.5 to 6.6%) for detemir and NPH, respectively (NS). In both groups, 70% of participants achieved an A1C of 7.0%, but the proportion achieving this without hypoglycemia was higher with insulin detemir than with NPH insulin (26 vs. 16%, P = 0.008). Compared with NPH insulin, the risk for all hypoglycemia with insulin detemir was reduced by 47% (P < 0.001) and nocturnal hypoglycemia by 55% (P < 0.001). Mean weight gain was 1.2 kg with insulin detemir and 2.8 kg with NPH insulin (P < 0.001), and the difference in baseline-adjusted final weight was –1.58 (P < 0.001)."

In short, it was found that insulin detemir reduced Hemoglobin A1C to target levels of 7.0% for 70% of patients, similar to human basal insulin NPH, but without the same risk of hypoglycemia (low blood sugar) and with much lower weight gain.

Similar results have been seen in type 1 diabetes (see ref 3.)

References

1. http://content.nejm.org/cgi/content/full/NEJMoa075392, Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes; Rury R. Holman, M.B., Ch.B., F.R.C.P., Kerensa I. Thorne, M.Sc., Andrew J. Farmer, D.M., F.R.C.G.P., Melanie J. Davies, M.D., F.R.C.P., Joanne F. Keenan, B.A., Sanjoy Paul, Ph.D., Jonathan C. Levy, M.D., F.R.C.P., for the 4-T Study Group

2. http://care.diabetesjournals.org/cgi/content/abstract/29/6/1269?ijkey=2e8d412f27ded6ae0a205b3bfd4d3608ed9b64b5&keytype2=tf_ipsecsha , A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes, Kjeld Hermansen, MD1, Melanie Davies, MD2, Taudeusz Derezinski, MD3, Gabrielle Martinez Ravn4, Per Clauson4, Philip Home, DM, DPHIL5 on behalf of the Levemir Treat-to-Target Study Group

3. http://www.springerlink.com/content/6lktug1r2exurq0j/?p=af5e2f613a0f4c6690f8fdc920f48bd6&pi=5 , Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes, Journal Diabetologia, Issue Volume 47, Number 4 / April, 2004.

External links

• http://www.genome.jp/dbget-bin/www_bget?dr:D04539

Template:WikiDoc Sources